Press Releases
Interim Report 1 January to 31 March 2022
12 May, 2022 08:30 CESTRegulatoryCyxone AB announces promising T20K/KORa combination therapy efficacy in preclinical therapeutic model of MS
3 May, 2022 10:07 CESTCyxone AB (CYXO) Introduced at the online HC Andersen Capital event on 29 April
28 Apr, 2022 13:23 CESTCyxone announces forward looking drug development strategy with focus on Rabeximod in Rheumatoid Arthritis trial
28 Apr, 2022 11:01 CESTAnnual Report from Cyxone AB for the period 1 January 2021 to 31 December 2021
13 Apr, 2022 16:48 CESTRegulatory